Sonoma Pharmaceuticals, Inc. (SNOA) shareholders
Close on Nov 17, 2026Market cap $3.99MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SNOA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 40,468 | 0.85% | $49.78K | New | 0.00% |
| Geode Capital Management, LLC | 26,787 | 0.56% | $32.95K | +6,846 | 0.00% |
| Vanguard Capital Management LLC | 18,787 | 0.39% | $23.11K | – | 0.00% |
| McKinley Carter Wealth Services, Inc. | 11,193 | 0.23% | $13.77K | – | 0.00% |
| UBS Group AG | 7,808 | 0.16% | $9.60K | +7,802 | 0.00% |
| Global Retirement Partners, LLC | 2,548 | 0.05% | $3.13K | New | 0.00% |
| Morgan Stanley | 2,000 | 0.04% | $2.46K | −4 | 0.00% |
| Osaic Holdings, Inc. | 500 | 0.01% | $615 | – | 0.00% |
| Barclays PLC | 459 | 0.01% | $565 | New | 0.00% |
| BlackRock, Inc. | 113 | 0.00% | $139 | – | 0.00% |
| Vanguard Fiduciary Trust Co | 100 | 0.00% | $123 | – | 0.00% |
| Harbour Investments, Inc. | 15 | 0.00% | $18 | New | 0.00% |
| Quaker Wealth Management, LLC | 3 | 0.00% | $4 | – | 0.00% |
| Danske Bank A/S | 1 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 14 | 0M | 2.3% | 4 / 2 | 1 / 6 | 0M | 0M |
| Q1 2026 | 17 | 0M | 1.4% | 4 / 4 | 1 / 1 | 0M | 0M |
| Q4 2025 | 16 | 0M | 2.3% | 2 / 3 | 5 / 6 | 0M | 0M |
| Q3 2025 | 20 | 0M | 1.2% | 8 / 2 | 1 / 2 | 0M | 0M |
| Q2 2025 | 14 | 0M | 1.8% | 4 / 3 | 2 / 2 | 0M | 0M |
| Q1 2025 | 12 | 0M | 0.7% | 3 / 1 | 2 / 0 | 0M | 0M |
| Q4 2024 | 9 | 0M | 0.4% | 0 / 2 | 2 / 5 | 0M | 0M |
| Q3 2024 | 14 | 0M | 0.6% | 14 / 0 | 0 / 1 | 0M | 0M |
| Q2 2024 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held SNOA in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SNOA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 18,787 | 0.39% | $23.11K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 13,934 | 0.29% | $15.88K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,528 | 0.05% | $2.88K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 2,314 | 0.05% | $2.64K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Poggetto John Dal | Controller | 15,000 | 0.31% | Jul 9, 2026 |
| Amy Moss Trombly | Chief Executive Officer | 153,586 | 3.21% | Jul 9, 2026 |
| Jerome J. Dvonch | Chief Financial Officer | 84,595 | 1.77% | Jul 9, 2026 |
| Bruce Thornton | Executive VP and COO | 154,411 | 3.22% | Jun 20, 2025 |
| Vanessa Jacoby | Director | – | – | Jul 9, 2026 |
| John McLaughlin | Director | 48,728 | 1.02% | Jul 9, 2026 |
| Philippe Weigerstorfer | Director | 22,500 | 0.47% | Jul 9, 2026 |
| Jay E. Birnbaum | Director | 51,659 | 1.08% | Jan 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jerome J. Dvonch Chief Financial Officer | Jun 20, 2024 | Award | +53,586 | – | – | 84,595 |
| Poggetto John Dal Controller | Jun 20, 2024 | Award | +15,000 | – | – | 15,000 |
| Bruce Thornton Executive Vice President | Jun 20, 2024 | Award | +53,586 | – | – | 154,411 |
| Amy Moss Trombly Chief Executive Officer | Jun 20, 2024 | Award | +53,586 | – | – | 153,586 |
| Amy Moss Trombly Chief Executive Officer | Jun 30, 2023 | Award | +100,000 | – | – | 213,648 |
| Bruce Thornton Executive Vice President | Jun 30, 2023 | Award | +100,000 | – | – | 216,781 |
| Poggetto John Dal Chief Financial Officer | Apr 23, 2020 | Award | +3,086 | – | – | 3,201 |
| Robert Grant Edwards Chief Financial Officer | Apr 23, 2020 | Award | +2,609 | – | – | 2,609 |
| John McLaughlin Director | May 30, 2018 | Award | +1,781 | – | – | 48,728 |
| Russell Joseph Harrison Director | May 30, 2018 | Award | +1,538 | – | – | 46,520 |
| Jay E. Birnbaum Director | May 30, 2018 | Award | +1,052 | – | – | 51,659 |
| Robert E. Miller Chief Financial Officer | Mar 13, 2018 | Buy | +1,200 | $4.10 | $4.92K | 18,868 |
| Robert E. Miller Chief Financial Officer | Mar 12, 2018 | Buy | +1,200 | $4.03 | $4.84K | 17,668 |
| Robert E. Miller Chief Financial Officer | Mar 12, 2018 | Buy | +1,200 | $4.03 | $4.84K | 16,468 |
| Robert E. Miller Chief Financial Officer | Mar 9, 2018 | Buy | +1,200 | $3.90 | $4.68K | 15,268 |
| James J. Schutz Chief Executive Officer, Director | Mar 8, 2018 | Buy | +2,473 | $3.99 | $9.87K | 35,858 |
| Sharon Barbari Director | Mar 1, 2018 | Award | +1,424 | – | – | 43,417 |
| Jay E. Birnbaum Director | Mar 1, 2018 | Award | +1,157 | – | – | 50,607 |
| John McLaughlin Director | Mar 1, 2018 | Award | +1,958 | – | – | 46,947 |
| Russell Joseph Harrison Director | Mar 1, 2018 | Award | +1,691 | – | – | 44,982 |
| John McLaughlin Director | Jan 2, 2018 | Award | +17,211 | – | – | 44,989 |
| James J. Schutz Chief Executive Officer, Director | Jan 2, 2018 | Award | +17,211 | – | – | 33,385 |
| Jay E. Birnbaum Director | Jan 2, 2018 | Award | +25,817 | – | – | 49,450 |
| Sharon Barbari Director | Jan 2, 2018 | Award | +17,211 | – | – | 41,993 |
| Russell Joseph Harrison Director | Jan 2, 2018 | Award | +17,211 | – | – | 43,291 |
| James J. Schutz Chief Executive Officer, Director | Nov 30, 2017 | Buy | +345 | $4.95 | $1.71K | 16,174 |
| John McLaughlin Director | Nov 29, 2017 | Award | +14,317 | – | – | 27,778 |
| Sharon Barbari Director | Nov 29, 2017 | Award | +13,944 | – | – | 24,782 |
| Russell Joseph Harrison Director | Nov 29, 2017 | Award | +14,130 | – | – | 26,080 |
| Jay E. Birnbaum Director | Nov 29, 2017 | Award | +13,757 | – | – | 23,633 |
| Robert E. Miller Chief Financial Officer | Nov 29, 2017 | Buy | +1,290 | $5.02 | $6.48K | 14,068 |
| Robert E. Miller Chief Financial Officer | Nov 29, 2017 | Buy | +500 | $5.03 | $2.52K | 12,778 |
| James J. Schutz Chief Executive Officer, Director | Nov 29, 2017 | Buy | +400 | $5.03 | $2.01K | 15,829 |
| James J. Schutz Chief Executive Officer, Director | Nov 24, 2017 | Buy | +254 | $5.05 | $1.28K | 15,429 |
| Robert E. Miller Chief Financial Officer | Nov 21, 2017 | Buy | +500 | $5.04 | $2.52K | 12,278 |
| Robert E. Miller Chief Financial Officer | Nov 21, 2017 | Buy | +1,500 | $5.03 | $7.55K | 11,778 |
| John McLaughlin Director | Aug 29, 2017 | Award | +1,210 | – | – | 13,471 |
| Jay E. Birnbaum Director | Aug 29, 2017 | Award | +715 | – | – | 9,876 |
| Sharon Barbari Director | Aug 29, 2017 | Award | +880 | – | – | 10,838 |
| Russell Joseph Harrison Director | Aug 29, 2017 | Award | +1,045 | – | – | 11,950 |
| Robert E. Miller Chief Financial Officer | Aug 10, 2017 | Buy | +2,264 | $5.30 | $12.00K | 10,728 |
| Marc Umscheid Chief Strategy/Mkt Officer | Aug 10, 2017 | Buy | +600 | $5.31 | $3.19K | 3,392 |
| James J. Schutz Chief Executive Officer, Director | Aug 10, 2017 | Buy | +929 | $5.46 | $5.07K | 15,175 |
| Marc Umscheid Chief Strategy/Mkt Officer | Jun 29, 2017 | Award | +2,042 | – | – | 2,792 |
| Robert E. Miller Chief Financial Officer | Jun 29, 2017 | Award | +4,124 | – | – | 20,088 |
| Robert Allen Northey Exe. VP of Research and Dev. | Jun 29, 2017 | Award | +3,404 | – | – | 8,082 |
| James J. Schutz Chief Executive Officer, Director | Jun 29, 2017 | Award | +2,406 | – | – | 14,246 |
| John McLaughlin Director | May 30, 2017 | Award | +1,036 | – | – | 12,261 |
| Sharon Barbari Director | May 30, 2017 | Award | +754 | – | – | 9,958 |
| Russell Joseph Harrison Director | May 30, 2017 | Award | +895 | – | – | 10,905 |
| Jay E. Birnbaum Director | May 30, 2017 | Award | +612 | – | – | 9,161 |
| Robert E. Miller Chief Financial Officer | Mar 9, 2017 | Buy | +250 | $7.14 | $1.79K | 8,464 |
| Robert E. Miller Chief Financial Officer | Mar 9, 2017 | Buy | +250 | $6.97 | $1.74K | 7,964 |
| Robert E. Miller Chief Financial Officer | Mar 9, 2017 | Buy | +250 | $6.96 | $1.74K | 8,214 |
| Robert E. Miller Chief Financial Officer | Mar 8, 2017 | Buy | +750 | $6.97 | $5.23K | 7,714 |
| Robert E. Miller Chief Financial Officer | Mar 8, 2017 | Buy | +250 | $6.81 | $1.70K | 6,964 |
| Marc Umscheid Chief Strategy/Mkt Officer | Mar 6, 2017 | Buy | +750 | $6.82 | $5.12K | 750 |
| James J. Schutz Chief Executive Officer, Director | Mar 3, 2017 | Buy | +104 | $6.75 | $702 | 11,840 |
| James J. Schutz Chief Executive Officer, Director | Mar 3, 2017 | Buy | +696 | $6.78 | $4.72K | 11,736 |
| Jay E. Birnbaum Director | Mar 1, 2017 | Award | +577 | – | – | 8,549 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sonoma Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,500 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Gottfurcht Grant 10% Stockholder | Jan 3, 2025 | 86,111 | $232.50K | Jan 3, 2025 | Open Market |
| Gottfurcht Grant 10% Stockholder | Jan 3, 2025 | 30,000 | $80.68K | Jan 2, 2025 | Open Market |
| Gottfurcht Grant 10% Stockholder | Jan 3, 2025 | 17,806 | $48.56K | Dec 31, 2024 | Open Market |
| Gottfurcht Grant Open Market | Jan 2, 2025 | 30,000 | $80.68K | Jan 2, 2025 | Open Market |
| Gottfurcht Grant Open Market Purchase | Jan 2, 2025 | 17,806 | $48.56K | Dec 31, 2024 | Open Market |
| Gottfurcht Grant 10% Stockholder | Dec 26, 2024 | 221,375 | $56.46K | Aug 9, 2024 | Open Market |
See a number that looks wrong?